Makers of top-selling drugs hike prices in lockstep, and patients bear the cost - STAT

Makers of top-selling drugs hike prices in lockstep, and patients bear the cost - STAT

STAT Plus: Extraordinary tactics, perverse incentives: Makers of top-selling drugs hike prices in lockstep, and patients bear the cost

By CASEY ROSS

KAYANA SZYMCZAK FOR STAT

The makers of two arthritis drugs increased their prices in lockstep from 2013-2018, reflecting their clout in a market where patients suffer blinding pain.

READ MORE